Abstract: Objective To investigate the clinical effects of butylphthalide injection combined with edaravone in the treatment of progressive cerebral ischemic stroke. Methods 90 patients with progressive cerebral ischemic stroke were divided randomly into three groups, 30 patients in each group. Patients in conventional group were given conventional treatment of ischemic cerebrovascular disease. Patients in control group were treated with edaravone on the basis of conventional treatment. Patients in observed group were given butylphthalide and edaravone on the basis of conventional treatment additionally. The three groups were treated continuously for 14 days. The degree of neurological deficit score (NIHSS) and daily life ability score (Barthel index) were compared respectively among the three groups just before and after treatment. Meanwhile compared the clinical effects and adverse reactions among the three groups.Results Both NIHSS and BI of the three groups were improved following the 14d treatment (F=7.652, 14.102, P<0.01), and the observation group was significantly better than the conventional group and the control group. The difference was statistically significant (P<0.05). The total efficiency of the observation group was 86.67%, which was obviously better than that of the conventional group(43.33%) and the control group (60.00%), the difference was statistically significant (H=12.243, P=0.002). No obvious adverse reaction occurred in the three groups.Conclusion Butylphthalide injection combined with edaravone in the treatment of progressive cerebral ischemic stroke can effectively alleviate nerve function damage, improve the ability of the patients’ daily life, which has higher clinical curative effects and less adverse reactions, is worth popularizing in clinical practices.

Key words: acute progressive cerebral ischemic stroke, butylphthalide, edaravone